International Stem Cell CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that International Stem Cell CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $7.46M | Apr 9, 2018 |
| FY2017 | Dec 31, 2016 | $7.17M | Apr 9, 2018 |
| FY2016 | Dec 31, 2015 | $7.55M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $7.02M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $6.15M | Mar 30, 2015 |
| FY2013 | Dec 31, 2012 | $4.57M | Mar 17, 2014 |
| FY2012 | Dec 31, 2011 | $4.53M | Mar 26, 2013 |
| FY2011 | Dec 31, 2010 | $1.57M | Mar 16, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.10M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $9.09M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.79M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.18M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $7.18M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.13M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $9.47M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $11.09M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $7.46M | Apr 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($418.0K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($209.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($131.0K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($331.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($899.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($2.72M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($4.27M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.13M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($6.07M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($1.08M) | Apr 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($267.0K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($68.0K) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($663.0K) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($183.0K) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.92M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($2.82M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($5.73M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($3.47M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($4.94M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($4.85M) | Apr 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $684.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $657.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $511.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $492.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $695.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $988.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.39M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $2.40M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $2.66M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.86M | Apr 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $13.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $929.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $332.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($1.30M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($341.0K) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($1.40M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.08M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($2.14M) | Apr 15, 2019 |
| FY2013 | Dec 31, 2013 | ($5.64M) | Mar 17, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $166.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $80.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $23.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $28.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $164.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $185.0K | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $112.0K | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $231.0K | Apr 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.82M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.17M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.39M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.14M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $4.95M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.29M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $6.62M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $7.80M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $6.86M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.05M | Apr 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.58M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.80M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $5.28M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.36M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.23M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.32M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.21M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $5.26M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | $4.80M | Apr 15, 2019 |
| FY2011 | Dec 31, 2011 | $2.11M | Mar 16, 2012 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.06M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($3.93M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | ($4.19M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | ($4.52M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | ($4.59M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($4.33M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($2.89M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $2.54M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $2.06M | Jun 1, 2020 |
| FY2018 | Dec 31, 2016 | $3.44M | Apr 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($111.10M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($110.69M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($110.48M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($110.35M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($110.01M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($109.12M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($106.39M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($106.66M) | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | ($104.53M) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | ($98.46M) | Apr 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $304.0K | Apr 9, 2018 |
| FY2017 | Dec 31, 2016 | $110.0K | Apr 9, 2018 |
| FY2017 | Dec 31, 2015 | $532.0K | Apr 9, 2018 |
| FY2016 | Dec 31, 2014 | $1.11M | Mar 31, 2017 |
| FY2015 | Dec 31, 2013 | $2.24M | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $654.0K | Mar 30, 2015 |
| FY2013 | Dec 31, 2011 | $1.34M | Mar 17, 2014 |
| FY2012 | Dec 31, 2010 | $5.78M | Mar 26, 2013 |
| FY2011 | Dec 31, 2009 | $727.0K | Mar 16, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 9, 2018 |
| FY2016 | Dec 31, 2015 | (1) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | (9) | Mar 30, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2018 | Dec 31, 2018 | 0 | Apr 15, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 9, 2018 |
| FY2016 | Dec 31, 2015 | (2) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | (10) | Mar 30, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.00M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 8.00M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 8.00M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 8.00M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 8.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 7.54M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 7.54M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 6.93M | Jun 1, 2020 |
| FY2018 | Dec 31, 2017 | 6.06M | Apr 15, 2019 |
| FY2017 | Dec 31, 2016 | 3.95M | Apr 9, 2018 |